OncoRes Medical Becomes Ziva Surgical, Marking a Pivotal New Chapter in the Future of Breast Cancer Surgery

Résumé détaillé

Building on over a decade of foundational research in quantitative micro-elastography, the Australian tissue intelligence company unveils a new identity as it advances the ELORA®…

Building on over a decade of foundational research in quantitative micro-elastography, the Australian tissue intelligence company unveils a new identity as it advances the ELORA® System toward commercialization

PERTH, Australia, Nov. 11, 2026 /PRNewswire/ -- OncoRes Medical today announced its evolution to Ziva Surgical, unveiling a new name and visual identity as the Australian tissue intelligence company enters a defining chapter in its mission to transform how solid tumor cancers are detected during surgery.

The story began with a small team in Perth determined to solve one of the most persistent challenges in cancer surgery: knowing, in real time, whether cancerous tissue remains. Building on more than a decade of research and engineering developing quantitative micro-elastography (QME), initially undertaken at the University of Western Australia and the Harry Perkins Institute of Medical Research, OncoRes Medical, now trading as Ziva Surgical, has advanced this pioneering science from a laboratory technique into the ELORA® System.

Today, approximately one in five women undergoing breast-conserving surgery face a second operation to remove residual cancer. Surgeons rely on sight, touch, specimen imaging, and clinical judgment to determine whether additional tissue should be removed, yet these methods can leave residual cancer undetected at the time of surgery.

Powered by QME technology, ELORA® is designed to translate the surgeon's sense of touch into objective, microscale imaging, and is intended to provide surgeons with quantitative maps of tissue stiffness and microarchitecture inside the surgical cavity, – helping them make decisions about what to remove and what to preserve when and where it matters most. Designed to complement, rather than replace, pathology, the system received FDA Breakthrough Device Designation in 2020 and is supported by an exclusive commercial license and more than 44 granted patents globally in key markets across 10 patent families.

As…

"T…

Début de l'article, extrait de PR Newswire. Pour lire la suite, ouvrez l'article chez le média.